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Abstract
Background: The involvement of placental lactogen (PL) in the regulation of foetal growth has been investigated
in different species by in vivo immunomodulation techniques. However, when circulating antibodies are present
together with the hormone, the procedure for hormonal measurement becomes considerably complex. The aim of
this study was the immunoneutralization of bovine placental lactogen (bPL) concentrations in bovine foetal
circulation by direct infusion of rabbit anti-bPL purified immunoglobulins (IgG) via a foetal catheter (in vivo study).
The ability of a RIA based on guinea pig anti-bPL antiserum, for the measurement of bPL concentrations in
samples containing exogenous rabbit anti-bPL immunoglobulins, was also analyzed in in vitro and in vivo
conditions.
Methods: Six bovine foetuses were chronic cannulated on the aorta via the medial tarsal artery. Infusion of rabbit
anti-bPL IgG was performed during late gestation. Pooled rabbit anti-bPL antisera had a maximal neutralization
capacity of 25 μg bPL/mL of immunoglobulin. Interference of rabbit anti-bPL immunoglobulin with
radioimmunoassay measurement using guinea pig anti-bPL as primary antibody was first evaluated in vitro.
Polyclonal anti-bPL antibodies raised in rabbit were added in foetal sera to produce 100 samples with known
antibodies titers (dilutions ranging from 1:2,500 till 1:1,280,000).
Result(s): Assessment of the interference of rabbit anti-bPL antibody showed that bPL concentrations were
significantly lower (P < 0.05) in samples added with dilutions of rabbit antiserum lower than 1:80,000 (one foetus)
or 1:10,000 (four foetuses). It was also shown that the recovery of added bPL (12 ng/mL) was markedly reduced in
those samples in which exogenous rabbit anti-bPL were added at dilutions lower than 1:20,000. Concentrations of
foetal bPL were determined in samples from cannulated foetuses. In foetuses 1 and 6, bPL concentrations
remained almost unchanged (<5 ng/mL) during the whole experimental period. In Foetus 3, bPL concentrations
decreased immediately after IgG infusion and thereafter, they increased until parturition.
Conclusion(s): The use of a bPL RIA using a guinea pig anti-bPL as primary antiserum allowed for the
measurement of bPL concentrations in foetal plasma in presence of rabbit anti-bPL IgG into the foetal circulation.
Long-term foetal catheterization allowed for the study of the influence of direct infusion of anti-bPL IgG on
peripheral bPL concentrations in bovine foetuses.
Introduction
Growth hormone (GH), prolactin (PRL), and placental
l a c t o g e n( P L )a r em e m b e r so faf a m i l yo fp o l y p e p t i d e
hormones that are thought to have arisen from a
common ancestral gene. GH and PRL are mainly
secreted by the anterior pituitary of all vertebrates,
whereas PL is uniquely observed in some mammalian
species and is secreted in the placenta by trophoblastic
cells. PL shares several structural and biological activ-
ities with GH and PRL. As reviewed by Goffin et al. [1],
classically, the GH receptor (GHR) was presented as the
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(PRLR) was considered specific for PRL and PL. It has
been also shown that both bovine (b) and ovine (o) PL
can bind to GHR [2,3]. The involvement of PL in the
regulation of foetal growth has been investigated in dif-
ferent species. In human (h), hPL might be a foetal
somatogenic hormone as suggested by the presence of
specific hPL receptors in foetal tissues and by the fact
that hPL but not hGH can stimulate amino acid uptake
and glycogenesis in foetal tissues [4]. The results from
studies in ruminant species in which PL levels were
altered by infusion of PL molecules into the maternal
and foetal circulations [5-7] have also suggested that PL
regulates foetal growth by stimulating uptake of mater-
nal nutrients to the foetus and by stimulating the foetus
to use the substrates.
Immunoneutralization of different hormones such as
ovine PL [8] and somatostatin [9] have also been con-
ducted in order to investigate endocrine growth path-
ways in vivo. However, when circulating antibodies are
present together with the hormone, the procedure for
hormonal measurement becomes considerably com-
plex. Different methods have been proposed to detect
and to eliminate this interference in radioimmunoassay
(RIA) systems [10]. These include serial dilutions of
the sample [11], polyethylene glycol precipitation [12],
blocking with nonimmune serum [13] and use of alter-
native antibodies reacting with epitopes and believed
to be distinct from those recognized by circulating
antibodies [14].
Recently, we have performed foetal cannulation in
bovine species in order to investigate the effect of
immunoneutralization of bovine placental lactogen
(bPL) on some hormonal parameters assumed to be
related to foetal growth [15]. Bovine PL binds both
somatogenic and lactogenic receptors with high affinity
[16]. In bovine species, PL concentrations have a very
particular distribution in maternal and foetal compart-
ments. Maternal concentrations remain under 2 ng/mL
during the whole pregnancy period, whereas foetal con-
centrations are higher, ranging from 25 to 30 ng/mL on
Day 90 of gestation and decreasing to 5-15 ng/mL near
term [17]. Despite all the knowledge generated to date,
the biological activity of bPL in foetal growth remains
largely unknown [18]. The placental origin of this hor-
mone [19] and the repartition of the hormone mainly in
the foetal circulation than in the maternal one constitute
major difficulties for in vivo investigations.
We designed the present study in order to analyze the
ability of a RIA based on guinea pig anti-bPL antiserum
for the measurement of bPL concentrations in foetal
samples containing exogenous rabbit anti-bPL antisera
under in vitro and in vivo conditions.
Materials and methods
Reagents
Most of chemical reagents used for RIA were purchased
from Merck (Darmstadt, Germany) with the exception
of sodium azide (NaN3;V e l ,L e u v e n ,B e l g i u m ) ,b o v i n e
serum albumin (BSA Fraction V; ICN Biochemicals Inc.,
Aurora, OH), detergent polysorbate (Tween 20™;F l u k a ,
Buchs, Switzerland), and polyethylene glycol 6000 (Vel).
Sephadex G-75 as well as
125I-Na were obtained from
Amersham Biosciences (Uppsala, Sweden). Lactoperoxi-
dase was purchased from Boehringer Ingelheim GmbH
Corp. (Ingelheim, Germany). Native glycosylated 33 kDa
form of bPL (nbPL; fraction 322), which was used as the
standard was purified in our laboratory (Laboratory of
Animal Endocrinology and Reproduction, University of
Liege). Recombinant bovine placental lactogen (rbPL)
used for radiolabeling was kindly provided by Dr. Parlow
(rbPL, Lot#AFP9152C; NHPP, NIDDK & Dr. Parlow,
USA).
Origin of anti-bPL antibodies
Polyclonal antisera (AS) used for RIA were raised in gui-
nea pig (AS#276) and rabbit (AS#295) against a highly
purified bPL preparation (33 kDa) [20] according to the
method of Vaitukaitis et al. [21]. The immunization pro-
tocol was approved by the Animal Ethics Committee of
the University of Liege (Dossier number 287).
Optimal dilution titers (20 to 30% binding ratio of the
radiolabeled rbPL (
125I-rbPL) to the antiserum in the
zero standard (B0) assay tube) were 1:130,000 for guinea
pig AS#276 and 1:400,000 for rabbit AS#295 [22].
For the infusion proposal (in vivo study), an immuno-
globulin (Ig) preparation was purified from a pool of
rabbit anti-bPL antisera (AS#277, AS#278, AS#282,
AS#284, AS#285, AS#286, AS#288, AS#289, AS#294,
and AS#296, 700 mL) by using the method previously
described by Harboe and Ingild [23]. The purified pre-
paration (containing rabbit IgG anti-bPL) was ultrafil-
tered in an Amicon Cell System (MW 10,000 Da cut-off
membranes) to reach a concentration of 5 mg Ig/mL, as
determined by Lowry’s method [24]. The purified Ig was
extensively dialyzed against 0.9% NaCl (4 baths of 20
liters, 4°C) and stored at -20°C until use.
Secondary antibodies used in double-antibody
precipitation systems
Rabbit anti-guinea pig and sheep anti-rabbit secondary
antibodies were obtained following the immunization
protocol of Vaitukaitis et al. [21].
Specificity of secondary antibodies was tested by add-
ing them to different samples containing primary guinea
pig or rabbit antibodies. In brief, 100 μLo fg u i n e ap i g
AS#276 (1:130,000), rabbit AS#295 anti-bPL (1:400,000),
or a mixture of both primary antisera (0.05:0.05 mL; vol:
vol) were incubated with 100 μLo f
125I-rbPL (25,000
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ing 300 μL of assay buffer (phosphate 0.05 M, pH 7.3
containing 0.1% BSA). After 24 h, 1 mL of PEG solution
containing 0.87% v:v sheep anti-rabbit Ig or 0.45% v:v
rabbit anti-guinea pig Ig were added to those tubes con-
taining guinea pig AS#276 and rabbit AS#295, respec-
tively. A further incubation (1 h 30 min) was realized at
room temperature (20 to 25°C). The tubes were then
washed with 2 mL of assay buffer containing 0.5%
Tween 20™ and centrifuged at 2,500 × g at 4°C for 30
min. The supernatant was discarded and the pellet was
counted in a gammacounter (LKB Wallac 126 multi-
g a m m ac o u n t e r ,T u r k u ,F i n l a nd) with a counting effi-
ciency of 75%.
Measurement of binding ratio of the anti-bPL antiserum
to the tracer
Binding ratio of anti-bPL antiserum to the tracer (B/T,
%) was measured in all bovine foetal samples. Briefly, 10
μL of each sample and 100 μLo f
125I-rbPL (25,000
cpm) were added in tubes containing 400 μL of assay
buffer. Samples were incubated overnight at room tem-
perature. The next day, bound and free fractions were
separated after addition of 1 mL of second-antibody
PEG solution containing 0.87% v:v sheep anti-rabbit Ig,
as described elsewhere [22].
Bovine PL measurement in foetal samples
Concentrations of bPL in bovine foetal samples were
measured by a double-antibody-binding RIA system. In
brief, duplicate aliquots of foetal samples (50 μL) and
100 μL of each point of nbPL standard curve (100, 50,
25, 12.5, 6.25, 3.12, 1.56, and 0.78 ng/mL) were dis-
pensed into conical tubes containing 300 μL of assay
buffer, then incubated with 100 μLo f
125I-rbPL (25,000
cpm) and 100 μL of diluted primary antibody (guinea
pig anti-bPL). Initial dilution of the antiserum was
1:130,000. The maximum binding (B0)w a sd e t e r m i n e d
by replacing standard nbPL by 100 μL of assay buffer.
The nonspecific binding (NSB) tubes contained 400 μL
of assay buffer and 100 μLo f
125I-rbPL. Total count
tubes (Tc) contained 100 μLo f
125I-rbPL. The following
day, for separation of bound and free fractions, 1 mL of
second-antibody PEG solution (0.05% v:v normal guinea
pig serum, 0.45% v:v rabbit anti-guinea pig antiserum,
0.4% w:v BSA, 0.05% w:v microcrystalline cellulose, 0.5%
w:v polyethylene glycol 6000 in phosphate buffer) was
added to all except the Tc tubes and a further incuba-
tion (1 h 30 min) was realized at room temperature.
The tubes were then washed with 2 mL of phosphate-
BSA-Tween 20™ buffer and centrifuged at 2,500 × g at
4°C for 30 min. The supernatant was discarded and the
pellet was washed again. The radioactivity was measured
in a gammacounter with an efficiency of 75%.
The minimal detection limit (MDL) was determined as
the mean concentration minus twice the standard
deviation of 20 replicates of the zero standard. Four
plasma samples with distinct bPL concentrations were
used to calculate intra-assay and inter assay variations.
In vitro study on foetal samples containing anti-bPL
exogenous antibody
Interference of exogenous rabbit (AS#295) anti-bPL pri-
mary antiserum with in vitro measurement of bPL con-
centrations was analyzed by adding different dilutions of
this antiserum to 5 bovine foetal samples containing the
following amounts of bPL: 8.9 ± 1.6 ng/mL (Foetus A),
10.0 ± 1.3 ng/mL (Foetus B), 17.5 ± 1.4 ng/mL (Foetus
C), 18.5 ± 1.9 ng/mL (Foetus D) and 21.3 ± 1.5 ng/mL
(Foetus E). The samples were collected at a slaughter-
house from 90- to 280-days-old bovine foetuses. The
foetal ages were determined by crown-rump measure-
ment [25]. Serum was allowed to clot, centrifuged (15
min at 1,500 × g), aliquoted, and stored at -20°C until
use.
In brief, 50 different stock solutions were prepared by
adding 100 μL of different dilutions of rabbit AS#295
(1:500 to 1:256,000) to 400 μL of each foetal sample.
Foetal samples were pre-incubated with diluted anti-
serum for 10 h (room temperature) before RIA analysis.
The final dilutions of rabbit antiserum ranged from
1:2,500 to 1:1,280,000.
A recovery test was carried out by adding to each foe-
tal sample (70 μL) 30 μL of phosphate-BSA buffer con-
taining 40 ng/mL of bPL to obtain a final concentration
of 12 ng/mL. Recoveries of bPL were calculated as the
observed/expected bPL concentrations. The final results
were expressed as the percent recovery of each tested
sample.
In vivo study in cannulated bovine foetuses
Six Holstein pregnant cows were used for this study.
The experimental protocol was approved by the ULg
Ethics Committee (Dossier number 125). Gestational
age on the day of surgery varied from approximately
180 days (6 months) to 249 days (8 months) post-inse-
mination. The cannulation of the medial tarsal artery
(polyvinyl catheter, 0.75 mm I.D × 1.45 mm O.D) was
based on the technique previously described by
Taverne et al. [26] with some modifications. In brief,
following general anesthesia with halothane and surgi-
cal preparation, the uterus was exposed through a
median incision on linea alba. The foetal hind limb
was identified by intra-abdominal palpation and moved
so that the foot could be presented in the abdominal
incision (Figure 1A). After an incision through the
uterine wall, foetal membranes were successively
incised and progressively fixed together by Collins for-
ceps (Figure 1B). The foetal limb was withdrawn from
the uterus until the anterior surface of the hock joint
was easily accessible. Care was taken to keep the loss
of foetal fluids to a minimum. The foetal medial tarsal
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nyl catheter (Figure 1C). The catheter was advanced
40-50 cm so as to lie in the dorsal aorta. And then,
the foetal catheter was fixed to the skin, and after foe-
tal tissues closure, the foetal leg was carefully returned
to the uterus. Approximately 50 to 60 cm of catheter
were inserted into the uterine cavity. The uterus was
then closed with two rows of continuous sutures (sim-
ple and Cushing) for foetal membranes and the uterine
wall. Before the mid-ventral skin was sutured, the free
extremity of the catheter was exteriorized through a
small incision on the left side of the abdominal wall.
The abdominal midline incision was closed using a
three-layer suture standard procedure. The catheter
was tunneled subcutaneously along the flank to the
most dorsal area of the left sublumbar fossa. Hypoder-
mic blind needles capped with Luer-lock injection caps
were inserted into the external end of the catheter.
The catheter was filled with 5 mL of a sterile hepari-
nized saline solution (0.9% NaCl containing 200 units
of heparin/mL) and kept into a plastic bag containing
a 50:50 v:v ethanol:distilled water solution.
In the morning following surgery, each cow was
placed in a pen where she remained until calving.
Cows were fed with grass hay twice a day and water
was available at all times. The external ends of the
catheters were transferred into a hood containing a
small container filled with 50% ethanol solution. The
catheter was flushed with 3 to 5 mL of sterile hepari-
nized saline (200 units of heparin/mL) once daily until
parturition.
Heparinized blood samples (3 mL) were taken from
foetuses by using strict aseptic procedures. Sampling of
foetal blood was begun on the fourth day after cannula-
tion and was performed on a daily basis, usually
between 8.00 and 12.00 a.m., until parturition. In most
cases, foetal samples could be obtained. However, in
some days, samples could not be withdrawn probably
due to the interference of a blood clot with the catheter
or due to the positioning of the foetal leg. After each
sampling, catheters were flushed and filled with 5 mL of
heparinized saline. All the collected samples were imme-
diately centrifuged at 1,500 × g (4°C) during 15 min.
Plasma was aliquoted in small volumes (500 μL) and
stored at -20°C until assayed for bPL as previously
described.
Infusion of rabbit anti-bPL IgG into the foetal circula-
tion begun on Days 6 to 14 after surgery. Table 1
describes the period of pregnancy, the volume and the
frequency of infusion of IgG anti-bPL in bovine foetal
circulation. In order to avoid any foetal contamination,
the IgG solution was filtered in a 0.2 μm sterile acrodisc
filter (Pall Life Sciences, Cornwall, United Kingdom)
immediately before injection.
Figure 1 Arterial cannulation in bovine foetuses.B o v i n ef e t a l
hind limb was identified by intra-abdominal palpation and moved
so that the foot lay in the maternal abdominal incision (A). After an
incision through the uterine wall and after opening of the fetal
membranes, they were progressively fixed together by Collins
forceps. The fetal limb was withdrawn from the uterus until the
anterior surface of the hock joint was easily accessible (B). The fetal
medial tarsal artery was exteriorized and catheterized with a
polyvinyl catheter (C).
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D e s c r i p t i v ed a t aa r es h o w na st h em e a no fv a l u e s
obtained from the experiments performed in duplicate
by using Statview program [27]. Statistical significance
was accepted at the P < 0.05 level.
The effects of antisera dilutions on bPL concentration
measurements (in vitro study) were analyzed using a
general linear model (Proc GLM, SAS) according to the
following model: Yij = ai + bj + eij, where Yij = differ-
ence in bPL concentration measured in control sample
and sample that received antisera, in animal i (i = 1 to
5) and at dilution j (1:1,280,000 to 1:2,500 step 2 dilu-
tion), ai = the effect of animal i, bj = effect of the dilu-
tion j, and eij is the random residual effect (N [22]). The
animal effect was considered as random and the dilution
one as fixed. The random intra-treatment variance in
control samples (samples which did not receive antisera)
was considered to over-estimate the real value of the
random residual variance. Thus, the effect of the treat-
ment was finally tested on the difference between resi-
dual variance and 2 times the mean variance associated
with the intra-treatment variability in control samples.
The ratio of the mean delta obtained at each dilution
level to this estimated residual variance was tested with
a student t-test for 4 degrees of freedom (5 animals -1).
A similar model was used for data relative to recovery
test, but the effect of treatment was simply tested on
residual variance owing to the fact that no blank control
was tested in this trial.
For the in vivo study, only bPL foetal profiles were
described. Not all data were available for every animal at
each time-point, largely because of failures in taking
samples from the catheters.
Results
Characteristics of RIA used for bPL measurement in foetal
samples
By using guinea pig anti-bPL antiserum, displacement of
the standard inhibition curve ranged from 98 to 13% of
binding (B/B0). The minimum concentration of bPL
detected by this RIA system was 0.02 ng/mL. The
bovine foetal samples showed parallel displacement to
the standard curves (data not shown). Nonspecific bind-
ing was 1%. The intra-assay coefficients of variation at
bPL concentrations of 14.0, 8.5, 5.5, and 1.6 ng/mL were
5.2, 5.4, 6.4, and 9.8%, respectively. Inter-assay coeffi-
cients of variation measured in the same samples were
9.6, 8.6, 7.8, and 11.0%, respectively.
Specificity of secondary antibodies
As shown in Table 2, rabbit anti-guinea pig antisera did
not precipitate the complex formed by
125I-rbPL and
rabbit anti-bPL primary antiserum. By contrast, sheep
anti-rabbit antisera were able to precipitate the guinea
pig complex formed by
125I-rbPL and the guinea pig
anti-bPL antiserum.
Measurements of foetal bPL in the presence of
exogenous anti-bPL antibodies (in vitro study)
Foetal concentrations of bPL were measured in the pre-
sence or absence of exogenous rabbit antibodies by
using guinea pig primary antiserum. The concentrations
of bPL before the addition of the antiserum ranged from
6.7 (Foetus A) to 22.6 ng/mL (Foetus 6). The binding
activity measured as B/T (%) ranged from 3 to 27% in
samples containing anti-bPL dilutions ranging from
1:1,280,000 to 1:2,500, respectively. Despite the use of a
guinea pig RIA system, in Foetus A, which gave the low-
est bPL levels, concentrations decreased by more than
50% when an antiserum dilution of 1:80,000 was added.
For the other foetuses, concentrations lower than 50%
Table 1 Days and doses of immunoglobulins infused into
the foetal circulation of cannulated foetuses.
Foetus Infusion IgG anti-bPL infused
per Day
Day of
pregnancy
Day after
surgery
Volume mg of
IgG
Foetus 1 238 6 1 × 8 mL 40 mg
Foetus 2 239 6
a 2 × 10 mL 100 mg
Foetus 3 249 14
a 2 × 10 mL 100 mg
Foetus 4 256 7
a 2 × 10 mL 100 mg
262 and 263 13
a and 14
a 2 × 10 mL 100 mg
271 to 276 22
a to 27
a 2 × 10 mL 100 mg
Foetus 5 243 6
a 2 × 10 mL 100 mg
258 21
a 2 × 10 mL 100 mg
Foetus 6 ≈ 6 months 8 1 × 4 mL 20 mg
2 0 1×8m L 4 0m g
41
a 2 × 10 mL 100 mg
61
a and 62
a 2 × 10 mL 100 mg
85
a 2 × 10 mL 100 mg
Immunoglobulins were raised in rabbits against a glycosylated native form of
bovine placental lactogen (nbPL).
aInfusion twice daily (interval between two consecutive infusions on the same
day varied from 9 to 12 h).
Table 2 Binding of primary rabbit (AS#295) or guinea pig
(AS#276) antisera raised against glycosylated native form
of bovine placental lactogen (nbPL) to the different
secondary antisera.
Secondary antisera Primary antisera B/T Cross reactivity
Rabbit anti-guinea pig Rabbit AS#295 0.8% -
Guinea pig AS#276 12.7% +
AS#276 + AS#295 12.5% +
Sheep anti-rabbit Rabbit AS#295 12.2% +
Guinea pig AS#276 8.0% +
AS#276 + AS#295 8.3% +
B/T: Binding activity (B) regarding added Tracer (T).
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serum addition) were observed when rabbit anti-bPL
sera were added at dilutions of 1:10,000 to 1:2,500.
The percentages of recovery of bPL in the presence of
exogenous rabbit anti-bPL in those foetal samples hav-
ing been added of 12 ng/mL of bPL were shown in
Table 3. Samples containing lower dilutions of rabbit
anti-bPL sera were not quantified exactly. The recovery
ranged from 42 to 48% at a rabbit anti-bPL dilution of
1: 2,500. The accuracy of the measurement showed a
significant increase (P < 0.05) when rabbit anti-bPL dilu-
tions were equal to or higher than 1: 20,000 (recovery
higher than 70%).
Measurement of foetal bPL in the presence of circulating
anti-bPL antibodies throughout late gestation
Figures 2 and 3 show the bPL concentrations as well as
the binding activity (B/T) of the infused rabbit anti-bPL
IgG measured in 6 cannulated foetuses during late
pregnancy.
Catheter of foetuses remained functional for the long-
est period (95 days) in Foetus 6, despite a brief
interruption in sampling between Days 30 and 38 (Fig-
ure 3). In Foetus 5 (Figure 3), catheter allowed blood
sampling only during 10 days (Days 4 to 13). In this ani-
mal, after an interruption of 5 days in blood collection,
the catheter was used to collect amniotic fluid during a
16-day period (data not shown). In the other 4 animals,
catheter remained functional allowing blood sampling
until 27 (Foetus 1) to 39 Days (Foetus 3) after the
surgery.
Before IgG infusion, plasmatic concentrations of bPL
ranged from 2.2 (Foetus 1) to 6.9 ng/mL (Foetus 2) at
236 and 239 days of pregnancy, respectively. Binding
activity measured before IgG infusion (nonspecific bind-
ing) ranged from 1.9 (Foetus 6) to 4.6% (Foetus 4).
After a single injection of 8 mL of IgG in Foetus 1,
bPL concentrations discreetly decreased from 1.9 to 1.1
ng/mL (Figure 2). In this foetus, concentrations of bPL
remained relatively constant until parturition (range
from 1.9 to 3.8 ng/mL). In Foetus 2, bPL concentrations
decreased on the day following the IgG infusion into the
foetal circulation. The day after, concentrations reached
Table 3 Recovery of 12 ng/mL of bPL added to five foetal samples (A to E) in the presence of different dilutions of
rabbit anti-bPL.
Initial serum: bPL (ng/mL) Identification of foetal sample Foetal bPL concentrations (ng mL
-1) and percentage of recovery
Rabbit anti-bPL dilutions
1:1,280,000 1:320,000 1:80,000 1:20,000 1:5,000 1:2,500
A: 8.9 ± 1.6 A+ 8.6 7.5 3.7 2.6 1.6 0.7
A* 20.6 19.5 15.7 14.6 13.6 12.7
A++ 20.5 19.0 13.9 11.3 6.9 5.4
Recovery (%) 99.4 97.4 88.3 77.3 50.4 42.9
B: 10.0 ± 1.3 B+ 11.5 7.6 6.3 6.0 1.5 0.7
B* 23.5 19.6 18.3 18.0 13.5 12.7
B++ 23.9 18.4 17.2 14.9 8.1 6.3
Recovery (%) 101.7 93.9 93.9 82.7 60.2 49.1
C: 17.5 ± 1.4 C+ 18.1 19.4 15.4 16.4 3.3 0.9
C* 30.1 31.4 27.4 28.4 15.3 12.9
C++ 29.5 28.5 23.8 20.7 10.7 5.3
Recovery (%) 98.1 90.8 87.1 72.8 70.1 41.4
D: 18.5 ± 1.9 D+ 20.3 21.0 14.6 12.4 6.6 0.9
D* 32.3 33.0 26.6 24.4 18.6 12.9
D++ 31.5 30.9 24.4 19.5 10.5 5.9
Recovery (%) 97.3 93.7 91.6 80.0 56.5 45.7
E: 21.3 ± 1.5 E+ 22.56 19.3 21.2 15.3 5.2 1.2
E* 34.56 31.3 33.2 27.3 17.2 13.2
E++ 35.60 28.8 30.6 20.2 11.2 6.3
Recovery (%) 103.01 92.2 92.2 74.1 64.8 47.7
+: Concentrations of bPL in the presence of different dilutions of rabbit anti-bPL;
*: Theoretical bPL concentrations after addition of 12 ng/mL of bPL;
++: Observed bPL concentration.
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parturition. In Foetus 3, bPL concentrations also
reached a peak two days after injection of IgG anti-bPL.
Thereafter, concentrations tended to increase until
parturition.
As detailed in Table 1, Foetus 4 received a succession
of infusions of bPL at 9-12-hour interval (Day 7, 13 to
14 and 22 to 27 after surgery). Interestingly, in this foe-
tus, bPL concentrations first decreased (Day 8) and
thereafter increased until Days 13-14, when the next
infusions were injected into the catheter. And then, bPL
concentrations increase significantly to reach higher
levels (14.0 ng/mL) at Day 25 after surgery. Just before
parturition, concentrations of bPL decreased to reach
11.0 ng/mL.
In Foetus 5, concentrations of bPL were measured for
a short time, decreasing to 0.5 ng/mL after IgG injec-
tion. In this animal, the catheter was stripped out of the
blood vessel and it remained in the amniotic compart-
ment from Day 18 onward (data not shown).
Finally, concentrations of bPL remained relatively con-
stant in the peripheral circulation of Foetus 6 during the
whole sampling period, despite successive injections of
purified anti-bPL IgG. Binding activities immediately
after IgG injections were comparable to those observed
in Foetuses 2 to 5 (B/T higher than 60%).
Discussion
Passive immunoneutralization of an endogenous factor
associated with establishment of its secretion pattern via
a frequent blood sampling constitutes a powerful tool
for dissecting the contribution of that factor to normal
endocrinological function [28]. Bovine placental lacto-
gen, also known as bovine chorionic somatomammotro-
pin, is believed to play a pivotal role in the growth and
development of the foetus by coordinating the maternal
metabolism and nutrient supply from the cow to the
foetus [29]. The predicted secreted form of bPL has 200
residues and its primary sequence exhibits 50% and 23%
homology to bovine prolactin (bPRL) and growth hor-
mone (bGH), respectively [16,30]. Native 30-33 kDa bPL
forms have been purified from the placenta of cows
[20,31-34] and some of them were successfully used to
raise antisera in rabbits [17,35]. In the present investiga-
tion, we described the use of a bPL-RIA system based
on guinea pig antiserum for measurement of foetal bPL
concentrations after immunoneutralization with rabbit
anti-bPL antibodies. Moreover, we described for the first
time a long-term foetal catheterization allowing follow-
ing up the changes in bPL concentration after injection
of purified anti-bPL IgG into foetal compartment.
Most of the studies describing the interference of
antibodies with immunoassay measurements were car-
ried out in human medicine concerning serum thyro-
globulin measurements in the presence of
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Page 8 of 12thyroglobulin auto-antibodies [36,37]. Many endocri-
nologists were also confronted with this problem when
investigating diabetes mechanism after administration
of exogenous insulin antiserum [38,39] or when inves-
tigating the physiological role of oPL following active
immunization of ewe-lambs against recombinant oPL
[40]. As stated by Schneider and Pervos [41], the mag-
nitude and direction of interference of endogenous or
exogenous antibody are determined by the affinity of
the first antibody, the species specificity of the second
antibody, and the volume of the serum used, among
others. In the present study, the use of a primary gui-
nea pig anti-bPL antiserum appropriately quantified
bPL concentrations in peripheral concentration of non-
immunized foetuses (concentrations ranging from 6.72
to 22.56 ng/mL). The range of bPL concentrations was
in agreement with previous findings with regards to
bovine foetuses by the use of rabbit anti-bPL anti-
serum [17,35,42]. Our results also showed that rabbit
anti-guinea pig secondary antibody was more specific
than sheep anti-rabbit antibody for the recognition of
primary antisera. However, in the in vitro study, when
rabbit primary antiserum was added at dilutions lower
than at 1:20,000, the recovery of bPL by use of guinea
pig primary antiserum decreased significantly (<80%).
So, measurement of bPL concentrations in the pre-
sence of exogenous rabbit anti-bPL by using guinea
pig anti-bPL primary antiserum can reduce but does
not eliminate completely the interference of exogenous
antibodies when present in higher titers. Moreover, as
observed in Table 3, high circulating antibody titers
led to a higher interference with the recovery of the
added amount of bPL (12 ng/mL). We suggest a
threshold exogenous anti-bPL level (titer 1:20,000 to
1:40,000) below which interference can be expected.
During the past decades, foetal catheterization in the
large domestic animal species has proven to be an
i m p o r t a n tt o o lt h a tc o n t r i b uted for the determination
of foetal hormonal profiles and for following up the
changes in the peripheral hormonal circulation after
imunomodulation bioassays. As early as in 1974, Com-
line et al. [43] studied the hormonal changes associated
with the artificial induction of labor in bovine foetuses
(240-260 days of gestation) by applying this technique
to inject cortisol, dexamethasone, and corticotrophin
to foetal circulation as well as to take blood samples
during a period of 20 days. In our study, foetal blood
samples could be successfully obtained during a long
period (10 to 95 days) after cannulation surgery. This
sampling period throughout late gestation was much
longer than those reported in the literature from ovine
(3 days [5]; 10 days [44]; 14 days [7]; 35 days [45]) and
bovine (4 days [46]; 15 days [26]; 24 days [47])
foetuses.
The use of passive immunoneutralization technique in
order to abolish an endogenous factor by using a speci-
f i ca n t i s e r ap r e d a t e st h ed i s c o v e r yt h a tp i t u i t a r yh o r -
mone secretion is pulsatile in nature [28]. This method
was used in studies on the endocrine function of several
hormones such as insulin [48], glucagon [49,50], lutei-
nizing hormone [51], and insulin-like growth factor-I
[52,53]. In order to investigate the physiological role of
placental lactogen, Waters et al. [8] infused ewes during
late gestation with goat anti-oPL antiserum in order to
neutralize oPL for at least 12 h. In their study, as well as
in ours, the potential interference of the infused anti-
serum with the RIA measurement was taken into con-
sideration. These authors used an antiserum generated
in a species other than that used to raise the RIA’sp r i -
mary antiserum (rabbit anti-bPL).
Studies on foetal growth endocrinology using foetal
cannulation technique were more frequently carried out
in ovine than in bovine species for obvious reasons
(cost, duration of pregnancy, accessibility to foetal com-
partment, housing structures, and others) [54]. However,
due to the intrinsic characteristic of oPL and bPL hor-
mones, it cannot be assumed that the results obtained
in the ovine model are adequate for better understand-
ing of PL physiology in the cow. As previously
described, while the placental oPL is almost secreted
entirely into the dam (with the foetal levels being 100-
fold lower) [55], in cows the bPL concentrations are
higher in foetal than in maternal compartments until
parturition [17]. Moreover, maternal concentrations of
oPL increase from 100 to 1,000 ng/mL between Days 70
and 130 of gestation [56], whereas maternal concentra-
tions of bPL remain under 2 ng/mL during the whole
pregnancy. Finally, oPL is a nonglycosylated protein,
whereas bPL is a glycosylated molecule.
The plasma levels of placental products are regulated
by the overall rate of biosynthesis at the source level,
utilization at the target tissue(s) level, and clearance
from the circulation. In foetuses 3 and 4, following
injection of purified anti-bPL IgG, concentrations of
b P Lt e n d e dt oi n c r e a s ei nf o e t a lc i r c u l a t i o n ,w h i c h
resembles the enhancement of in vivo GH activity by
anti-GH antibodies [57-59]. The precise mechanism by
which anti-bPL antibodies enhance bPL concentrations
is not clear. Short half-lives were estimated for some PL
molecules, approximately 10.5 min and 7.5 min for
[
125I]oPL and rbPL, respectively [16]. However, consid-
ering that native bPL is a glycosylated molecule, half-life
may be probably longer than that of rbPL. Another pos-
sible explanation could be that the complex formed by
the infused anti-bPL IgG antibodies and free bPL pro-
tects this molecule from the degradation, prolonging its
half-life. It is also possible that anti-bPL may induce
changes in the molecular structure of bPL, increasing its
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Page 9 of 12affinity for its receptor or decreasing hormone-receptor
internalization rate. Enzymatic removal of N-linked oli-
gosaccharide from bPL increased the affinity for its
receptor by approximately two-fold [16]. An alternative
explanation for the increase in the bPL concentrations
in peripheral circulation of Foetuses 3 and 4 is that the
immunoneutralization of bPL activity led to an increase
in bPL synthesis and secretion by the placenta through
an altered feedback mechanism, as a compensatory
“rebound effect”.
In the present in vivo study, detection of rabbit anti-
bPL IgG was possible in all the infused foetuses. The
attained titers (dilutions giving up to 50% of specific
antibody binding) were comparable to those values and
to the variability of responses reported after immuniza-
tion with hormones such oPL [40]. The infusion of anti-
bPL IgG immediately immunoneutralized the circulating
bPL, as reported by Waters et al. [8]. Before the infusion
of anti-bPL, basal concentrations of bPL are in accor-
dance with those reported by different authors [17,22].
After bPL immunoneutralization, a rapid decline of anti-
bPL was observed, alleviating the neutralization effect.
This decrease is probably due to the combined effect of
degradation, clearance from the circulation, and filling
of available binding sites with endogenous bPL.
In rat, responses to GH have been shown to vary
depending on the pattern of GH administration. GH
injections have a more pronounced effect on total body
weight gain, whereas a constant infusion of GH leads to
selective organ growth and reduction in size of fat pads
[60]. As seen in Table 1, the infusions were made occa-
s i o n a l l y ;w ed i dn o tu s ea n yd e v i c et oi n f u s ea n t i - b P L
continuously for a long period.
In summary, our data demonstrated the feasibility and
utility of a bPL-specific assay using a guinea pig anti-
bPL antiserum in investigations based on neutralization
of circulating bPL by means of direct injection of rabbit
immunoglobulins into the foetal circulation. In addition,
long-term foetal catheterization in late gestation has
proven to be realizable and can be proposed as a tool
to investigate foetal endocrinology during late
pregnancy.
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